MedPath

Polycaprolactone / Tricalcium Phosphate (PCL/TCP) v Titanium Orbital Implant : Randomised Trial

Phase 2
Conditions
Fractures
Enophthalmos
Diplopia
Interventions
Device: Polycaprolactone / Tri-Calcium Phosphate
Device: Titanium Mesh
Registration Number
NCT01119144
Lead Sponsor
National University Hospital, Singapore
Brief Summary

Hypothesis: Polycaprolactone / Tricalcium Phosphate Orbital (PCL / TCP) Implant is as effective in the reconstruction of the Orbital walls as Titanium Mesh implant.

In this study we will be conducting a randomised trial to compare implants made of 2 materials for Orbital reconstruction

* Polycaprolactone / Tricalcium Phosphate (PCL / TCP)

* Titanium

Patients to be recruited :

* 80 randomised equally into the 2 groups

* age range: 21 - 70

* includes orbital wall defects from trauma, after osteotomies

* excludes patients with Diabetes Mellitus, known allergies to polycaprolactone \& its analogues, know allergies to Tricalcium Phosphate \& its analogues, infections generalised \& around the orbital region

Trial Duration: April 2010 - March 2015

Follow up:

* postoperative 1 week, 1 month, 3 months, 6 months, and 12 months

* Computer Tomographic (CT) scan of Orbits immediate postoperative and at 12 months appointment

Detailed Description

Hypothesis: Polycaprolactone / Tricalcium Phosphate (PCL / TCP) Orbital Implant is as effective in the reconstruction of the Orbital walls as Titanium Mesh

In this study we will be conducting a randomised trial to compare implants made of 2 materials for Orbital reconstruction

* Polycaprolactone / Tricalcium Phosphate (PCL / TCP)

* Titanium

Patients to be recruited :

* 80 randomised equally into the 2 groups

* age range: 21 -70

* includes orbital wall defects from trauma confirmed by Computer Tomographic (CT) scans, after osteotomies

* excludes patients with Diabetes Mellitus, known allergies to polycaprolactone \& its analogues, know allergies to Tricalcium Phosphate \& its analogues, infections generalised \& around the orbital region

Trial Duration : April 2010 - March 2015

Follow up:

* postoperative 1 week, 1 month, 3 months, 6 months, and 12 months

* Computer Tomographic (CT) scan of Orbits immediate postoperative and at 12 months appointment

* all patients will be seen \& assessed in the Plastic \& Ophthalmology outpatient clinics by Principal Investigator (PI) and collaborators

End point :

* endpoint for follow-up is 12 months

* all patients are assessed for assessed for diplopia, enophthalmos, exophthalmos, visual acuity, mobility of the globe, contour symmetry

* all patients will have a Computer Tomographic (CT) scan of the orbits at 12 months to assess the bony orbit \& orbital volume

* patients will be discharged from follow up at 12 months if asymptomatic

* patients with complications will exit the protocol \& will be treated on their merits eg. infection - removal of implant, etc

Data Management :

* maintained by the Principal Investigator (PI) under repository of the Research \& Development Office, National Healthcare Group (NHG) / National University Health Systems (NUHS), Singapore

* no data will be released without the permission of the Principal Investigator (PI) \& the Research \& Development Office, National Healthcare Group (NHG) / National University Health Systems (NUHS), Singapore

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
80
Inclusion Criteria
  • age 21 y - 70 y
  • both males / females included
  • orbital fractures
  • defect after orbital osteotomies
Exclusion Criteria
  • patient refusal
  • infection around the orbit / generalised infection
  • Diabetes mellitus
  • allergies to polycaprolactone & its analogues
  • allergies to titanium

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Polycaprolactone / Tricalcium PhosphatePolycaprolactone / Tri-Calcium PhosphatePolycaprolactone / Tricalcium Phosphate group to assess efficacy of new implant
ControlTitanium MeshControl group with titanium mesh
Primary Outcome Measures
NameTimeMethod
Enophthalmos1 year

Assess the presence of enophthalmos after reconstruction of the orbital walls at 1 week, 1 month, 3 months, 6 months and 12 months

Secondary Outcome Measures
NameTimeMethod
Diplopia1 year

Assess the evidence of diplopia on follow up at 1 week, 1 month, 3 months, 6 months and 12 months

motility of the globe1 year

assess globe motility on follow up at 1 week, 1 month, 3 months, 6 months, and 12 months

Trial Locations

Locations (1)

National University Hospital

🇸🇬

Singapore, Singapore

© Copyright 2025. All Rights Reserved by MedPath